Stock Analiz

Bicara Therapeutics Inc. (BCAX) stock forecast and price target

Price $10.02 · data as of November 13, 2026

12-month price target

Average target$32.17
Upside / downside+221.0%
Analysts12
ConsensusStrong buy
Low $8.00Average $32.17High $43.00

Gold marker: average target · white marker: today’s price ($10.02)

Analyst ratings

Strong buy 3Buy 10Hold 0Sell 1Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-3.63−44.0%$0
Next fiscal year
ends December 31, 2027
$-3.89−7.3%$0
Next quarter
ends December 31, 2026
$-0.86−26.6%$0
Quarter after
ends March 31, 2027
$-1.01−9.1%$0

Consensus of the analysts covering Bicara Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 1 lowered.

Frequently asked questions

What is the Bicara Therapeutics stock price target?

The average 12-month target from 12 analysts is $32.17, 221.0% above the current price of $10.02 Targets range from $8.00 to $43.00.

Is Bicara Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (3 strong buy, 10 buy, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is Bicara Therapeutics expected to earn?

Analysts expect EPS of $-3.63 for the fiscal year ending December 31, 2026 and $-3.89 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.